Full-Time

Associate Medical Excellence & Training Director

Posted on 9/10/2026

United Therapeutics Corporation

United Therapeutics Corporation

Biotech company develops PAH therapies

Compensation Overview

$182.5k - $240k/yr

Delaware, USA + 13 more

More locations: Research Triangle Park, Durham, NC, USA | Connecticut, USA | Florida, USA | New Hampshire, USA | Philadelphia, PA, USA | South Carolina, USA | Georgia, USA | Virginia, USA | Rhode Island, USA | New York, NY, USA | Maine, USA | North Carolina, USA | New Jersey, USA

Remote

Ideal candidates live on the East Coast. Travel up to 40% is required.

Bachelor's, Master's, PharmD, PhD, MD

Category
Biology & Biotech

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Requirements
  • A Bachelor's degree, preferably in life sciences, with 12 or more years of experience in Medical Affairs supporting specialty care compounds or products or clinical practice in pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, or interstitial lung disease patient care, or an equivalent combination.
  • A Master's degree, Nurse Practitioner, or Physician Assistant qualification in a relevant clinical area, preferably with 10 or more years of experience in Medical Affairs supporting specialty care compounds or products or clinical practice in pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, or interstitial lung disease patient care, or an equivalent combination.
  • A Doctor of Pharmacy or Doctor of Philosophy degree in a relevant clinical area, preferably with 7 or more years of experience in Medical Affairs supporting specialty care compounds or products or clinical practice in pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, or interstitial lung disease patient care.
  • At least 3 years of industry Medical Affairs experience in healthcare-professional-facing roles.
  • At least 3 years of clinical or Medical Affairs experience in pulmonary arterial hypertension or interstitial lung disease therapeutic areas.
  • Current working knowledge of local legal, regulatory, and compliance regulations and guidelines relevant to industry interactions with healthcare professionals.
  • Ability to operate effectively in ambiguity, solve problems productively, and adapt to changing conditions.
  • Ability to develop strategic plans, goals, and objectives.
  • Ability to communicate effectively with all levels of leadership and individual contributors.
  • Experience partnering effectively and cultivating and maintaining collaborative relationships across functions and departments.
  • Excellent communication, presentation, organizational, and time-management skills.
  • Ability to coordinate and implement multiple projects within a complex matrix environment and communicate technical information to a diverse audience.
  • A proactive and innovative mindset.
  • Ability to travel up to 40%.
Responsibilities
  • Plan, design, implement, and evaluate training programs for new hires and continuing education of Medical Science Liaisons and other Global Medical Affairs colleagues.
  • Oversee the development of timely, accurate, and strategic field resources in collaboration with Medical Communications and Medical Information teams.
  • Drive the integration of materials into field platforms and department-wide communications, and maintain the Veeva Portal, Mobile Locker, and X-Fly Medical Insights systems.
  • Assist senior leaders with medical-insights queries and special projects.
  • Collaborate with Global Medical Affairs hiring managers to develop tailored onboarding plans for each new hire, oversee mentoring, facilitate new-hire training meetings, and maintain current onboarding materials.
  • Assist occasionally with onboarding non-Global Medical Affairs new hires who need clinical training.
  • Execute training programs using classroom training, demonstrations, on-the-job training, role play, self-study, meetings, conferences, workshops, videoconferencing, and web-based learning.
  • Coordinate planning and delivery of ongoing technical training and professional-development learning programs for field medical and internal Global Medical Affairs functions.
  • Participate in the field-resources workstream and oversee the development and updating of slides, frequently asked questions, talking points, and related resources.
  • Partner with Global Medical Affairs, product development, and global subject-matter experts to develop and execute disease- and product-related training.
  • Prepare budgets and justify funds required to perform proposed work with guidance.
  • Develop and adjust training and learning plans based on required competencies, organizational changes, and other external factors.
  • Conduct learning-needs assessments for Medical Affairs functions to determine training needs and priorities based on projected goals and plans.
  • Collaborate with cross-functional partners to prioritize and monitor changing educational needs of field medical, and work with field directors to identify training needs and develop and execute plans.
  • Participate in multiple internal workstreams and initiatives as appropriate.
  • Monitor changes in Medical Affairs strategy so that the training strategy remains relevant, and propose, plan, and develop new learning programs or improve existing programs based on project strategy and priorities.
  • Evaluate instructor performance and learning-program effectiveness and provide recommendations for improvement.
  • Oversee the sourcing and logistical management of trainers and external vendors or key opinion leaders as required.
  • Identify knowledge gaps and design training to address them.
  • Identify new treatment paradigms and guidelines in each relevant therapeutic area.
  • Work with compliance to ensure all work follows United Therapeutics policies and standards.
  • Lead development of Key Intelligence questions with input from Medical Affairs leadership.
  • Plan and execute pre-conference data reviews for internal teams and all Global Medical Affairs functions, and ensure United Therapeutics data is approved and ready for field use after presentation.
Desired Qualifications
  • Prior curriculum-development experience, education-outcome assessment experience, and application of adult-learning principles.
United Therapeutics Corporation

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Durham, North Carolina

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 Tyvaso DPI grew 4%, offsetting declines in nebulized Tyvaso and Remodulin.
  • United Therapeutics bought Thymmune on July 2, 2026, broadening transplant-tolerance and immune programs.
  • August 2026 Merrimack purchase adds 300 acres for 3D organ and manufacturing expansion.

What critics are saying

  • Tyvaso nebulized sales fell 18% in Q2 2026, exposing franchise cannibalization.
  • LungFX deployment starts in 2027, delaying revenue while development spending continues.
  • Xenotransplantation remains existentially unproven; any FDA trial failure cripples Rothblatt's organ-manufacturing thesis.

What makes United Therapeutics Corporation unique

  • United Therapeutics runs FDA-approved PAH brands, plus proprietary LungFX and xenotransplant platforms.
  • LungFX earned FDA PMA on June 29, 2026 for centralized ex vivo lung perfusion.
  • Its Stewartville DPF facility opened August 12, 2026, scaling gene-edited pig organs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

401(k) Retirement Plan

401(k) Company Match

Paid Time Off

Paid Holidays

Paid Vacation

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Conference Attendance Budget

Professional Development Budget

Professional Certification Support

Tuition Reimbursement

Stock Options

Company Equity

Employee Stock Purchase Plan

Relocation Assistance

Employee Referral Bonus

Performance Bonus

Profit Sharing

Sabbatical Leave

Hybrid Work Options

Remote Work Options

Flexible Work Hours

ParentAL Leave

Company News

Carla Gericke
Sep 3rd, 2026
Did Dolly die of her own advice? The independents.

Did Dolly die of her own advice? The independents. Dolly Parton put $1 million into Vanderbilt's early Moderna-related research, sang "Vaccine, vaccine, vaccine, vaccine" to the tune of Jolene, told "cowards" not to be a "chicken squat" - and died at 80 after a brief battle with cancer her team never named. This episode is not a coroner's report. It's about the advice, the playbook, and people on a ship who now say they regret the shot. Self-ownership is the relationship to yourself. Informed consent is the relationship to everyone else. COVIDmania smashed both: hide the downside, ban the question, mandate the product, zero manufacturer liability - then call it a "choice." Also on this show: the Tom Woods cruise, a note from every dinner table (regret vs blame), Fauci-world "delete this, then delete it from trash," and the old Anheuser-Busch campus in Merrimack sold to United Therapeutics, a company specializing in rare-disease work, xenotransplantation, organ printing. Not a data center. Worth eyeballs. If you own the body, you own the guess. The state does not live with the side effects. You do. carlagericke.com Chapters 0:00 Live from the Free State 0:38 Back from holiday / pledge from the porch 1:12 What's on the show 2:01 Merrimack campus sold - United Therapeutics 4:41 Did Dolly die of her own advice? 6:06 Why Dolly still mattered 7:35 Tom Woods cruise 10:43 Regret on the boat 13:25 Vaccines as the frame for self-ownership 16:05 My body, my choice - until it wasn't 17:32 Self-ownership vs informed consent 19:13 The celebrity playbook 20:13 Experimental + no liability = not consent 21:28 What happens when the experts are wrong 23:33 Three conditions for real consent 26:31 Should this go in my body? 27:38 Latency, the kicked can, closing #DollyParton #InformedConsent #SelfOwnership #Covid #NewHampshire #FreeState #TomWoods #Independence #CarlaGericke #Covidmania BONUS! What is xenotransplantation? Xenotransplantation is putting an organ or tissue from one species into another. In the news it almost always means pig | human. Not sci-fi printing from scratch. A pig is bred (usually gene-edited so the human immune system is less likely to attack the organ), the kidney or heart is taken out, and surgeons sew it into a person who would otherwise die waiting for a human donor. Why they want it Human organs are scarce. Thousands die on waitlists. A pig organ is a proposed spare. Why it sounds "sus" * Animal viruses riding along (PERVs - pig viruses) * Immune rejection, even with edits * First patients have been last-ditch cases; some lived weeks or months, not a settled spare-parts aisle * Ethics: breeding animals as organ farms * "Organ printing" is a different pitch (cells + scaffold in a lab). Companies sometimes sell both stories on one campus. United Therapeutics angle They work on lungs/pulmonary disease and have been in the pig-organ / bioengineered-organ lane. Buying a big campus does not mean Merrimack is growing chimeric zombies. It means a firm that wants to industrialize replacement parts now has square footage. One-line for air Xeno = animal organ in a human. The bet is pigs. The risk is viruses, rejection, and a factory logic for bodies. Worth watching. Not the same sentence as "they printed a person."

The New Hampshire Union Leader
Sep 2nd, 2026
Anheuser-Busch plant in Merrimack sold to United Therapeutics for $47.5M.

Anheuser-Busch plant in Merrimack sold to United Therapeutics for $47.5M. * DAVID LANE/UNION LEADER The Anheuser-Busch Merrimack Brewery site (shown here on Wednesday) was sold to United Therapeutics Corporation.

Forum Communications
Sep 1st, 2026
Stewartville's xenotransplant pig facility is ready for animals.

Stewartville's xenotransplant pig facility is ready for animals. United Therapeutics Corp.'s new $110 million "Designated Pathogen-Free" facility is completed in Stewartville's Schumann Business Park and ready to start raising gene-edited pigs to provide transplant organs for humans. Today at 6:25 AM News Reporting STEWARTVILLE, Minn. - A new $110 million "Designated Pathogen-Free" facility is complete and ready to start raising gene-edited pigs to provide transplant organs for humans. United Therapeutics Corp., a $14 billion Maryland-based biotech company behind the first successful pig-to-human heart and kidney transplants, recently hosted a private ribbon-cutting to unveil its newly built complex in Stewartville's Schumann Business Park. Keep Watching First-ever outdoor volleyball match in Minnesota finishes indoors The complex is called the Thomas E. Starzl Xenograft Production Facility in honor of the man who is known as the "Father of Organ Transplantation." Rodney Lam, associate vice president of Xeno Technical Operations with United Therapeutics, explained as he walked the 65,000-square-foot facility that it is now ready for pigs, with a capacity of 150 animals. A team of about 25 people will operate the Starzl Xenograft Production Facility, which raises the animals in pens that combine features of a high-end hog farm and a sterile clean room. Employees will wear protective suits while working with the animals. All of the equipment and products that enter the animals' clean area are sterilized with a shower of hydrogen peroxide. "Essentially, what we've engineered is a building within a building that is meant to keep it as clean as possible," he said. "Ultimately, we want to maintain a herd that is as clean and healthy as possible, so the pigs can become donors for human patients." The facility features its own labs and veterinarian clinic as well as two surgical units. A 3,600-panel solar farm next to it can produce up to 1.4 megawatts of electricity to help offset the facility's power needs. United Therapeutics conducted the first successful pig-to-human heart transplant in 2022 and the first pig-to-human kidney transplant in 2024. It is currently working with the U.S. Food and Drug Administration on clinical trials of xeno-organs with the goal of having pig-to-human transplants approved by the FDA by the end of the decade. In a world where the demand for organs for life-saving transplant continues to grow, United Therapeutics CEO and founder Dr. Martine Rothblatt is investing millions of dollars to eventually create an unlimited supply of organs. The Stewartville facility is one of three similar xenotransplant sites, with the others in Christiansburg, Virginia, and Houston, Texas. While UT's success is largely built on drugs to treat pulmonary arterial hypertension and a type of pediatric cancer, Rothblatt is committed to solving the need for organs. In addition to the xenotransplant sites, UT also has divisions working on regenerative and 3D printing solutions. "Dr. Rothblatt very much believes in multiple shots on goal," said Lam. In addition to the Starzl Xenograft facility, United Therapeutics paid more than $8.5 million in April to buy 200 acres of open farmland between Stewartville and Rochester along Interstate 90, U.S. Highway 63 and 90th Street Southwest with the goal of adding future facilities to support the nearby Stewartville site.

Longevity.Technology
Aug 31st, 2026
United Therapeutics presents positive Phase 3 lung disease study data.

United Therapeutics presents positive Phase 3 lung disease study data. United Therapeutics will present four oral and four poster presentations at the European Society of Cardiology Congress 2026, 28-31 August in Munich, and at the European Respiratory Society Congress 2026, 5-9 September in Barcelona. Late-breaking analyses from the phase 3 ADVANCE OUTCOMES study indicate ralinepag achieved clinical improvement in a lower-risk pulmonary arterial hypertension population and reduced clinical worsening in PAH patients with connective tissue disease, according to the company. Analyses from the phase 3 TETON program show nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit versus placebo in idiopathic pulmonary fibrosis patients. Additional presentations feature interim ARTISAN data on parenteral treprostinil and preliminary PHINDER findings on screening for pulmonary hypertension associated with interstitial lung disease. In June 2026, the company submitted a New Drug Application for ralinepag and a supplemental New Drug Application for nebulized treprostinil to the U.S. Food and Drug Administration; both agents remain investigational.

Investor's Business Daily
Aug 12th, 2026
Liquidia drops 4% despite $170M Yutrepia sales beat, misses earnings by 2 cents

Liquidia shares fell more than 4% on Wednesday despite the company's lung disease drug Yutrepia beating second-quarter sales expectations. The treatment generated $170.4 million in sales, growing 31% and surpassing forecasts of $166.4 million. However, the company posted earnings of 74 cents per share, slightly missing expectations of 76 cents. Yutrepia, which launched in June 2025, competes with United Therapeutics' Tyvaso in treating high blood pressure in the lungs. Since launch, Liquidia has received approximately 5,900 new patient prescriptions, with more than 5,000 patients starting treatment. Over 1,100 physicians now prescribe the drug. Liquidia stock has gained 155% year-to-date and ranks second on the IBD 50 list of elite growth stocks.